REC-994 + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cerebral Cavernous Malformation

Conditions

Cerebral Cavernous Malformation

Trial Timeline

Mar 17, 2022 → Jun 30, 2025

NCT ID

NCT05085561

About REC-994 + Placebo

REC-994 + Placebo is a phase 2 stage product being developed by Recursion Pharmaceuticals for Cerebral Cavernous Malformation. The current trial status is completed. This product is registered under clinical trial identifier NCT05085561. Target conditions include Cerebral Cavernous Malformation.

What happened to similar drugs?

5 of 17 similar drugs in Cerebral Cavernous Malformation were approved

Approved (5) Terminated (1) Active (12)

✅mouse nerve growth factorSun PharmaceuticalApproved

🔄Oral Glycopyrrolate LiquidShionogiPhase 3

🔄NXY-059AstraZenecaPhase 3

✅RosuvastatinAstraZenecaApproved

🔄NXY-059AstraZenecaPhase 3

🔄Recombinant Factor VIIa + Biological/Vaccine: PlaceboNovo NordiskPhase 3

🔄Recombinant Activated Factor VII (rFVIIa) + PlaceboNovo NordiskPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05085561	Phase 2	Completed	Mar 17, 2022	Jun 30, 2025	Cerebral Cavernous Malformation

Competing Products

20 competing products in Cerebral Cavernous Malformation

See all competitors

Product	Company	Stage	Hype Score
mouse nerve growth factor	Sun Pharmaceutical	Approved	39
Edaravone Dexborneol + Placebo	Sun Pharmaceutical	Phase 2	31
Oral Glycopyrrolate Liquid	Shionogi	Phase 3	40
recombinant human erythropoietin alfa + 0.9% NaCl	Johnson & Johnson	Phase 2/3	38
UDI-001	Rohto Pharmaceutical	Phase 1/2	32
NXY-059	AstraZeneca	Phase 3	40
NXY-059	AstraZeneca	Phase 2	35
Rosuvastatin	AstraZeneca	Approved	39
NXY-059	AstraZeneca	Phase 3	40
Comparator: Placebo + Comparator: MK0724	Merck	Phase 2	27
Vorapaxar 2.5 mg + Vorapaxar 1 mg + Placebo + Aspirin 75-150 mg	Merck	Phase 2	35
Recombinant Factor VIIa + Biological/Vaccine: Placebo	Novo Nordisk	Phase 3	47
Recombinant Activated Factor VII (rFVIIa) + Placebo	Novo Nordisk	Phase 3	44
Ponezumab	Pfizer	Phase 2	35
PF-05230907	Pfizer	Phase 1	21
Azithromycin + Pyrimethamine + Leucovorin calcium	Pfizer	Phase 1	29
clopidogrel (SR25990C)	Sanofi	Approved	43
Intrarectal quinine	Sanofi	Phase 3	36
Piracetam	UCB	Approved	35
Placebo + ALN-APP	Alnylam Pharmaceuticals	Phase 2	39